Pharmanutra s.r.l.   Report issue

For profit Phase 3
Founded: Pisa Italy (2003)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2008
NCT00749307
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Pharmanutra S.p.a.

Active Ingredients

Drugs in Phase 3 Trials (1)

docosahexaenoic acid (1 trial)

Drugs in Other Trials (1)

aprepitant (Emend) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arrhythmias, Cardiac (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2